|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 9,149,579
U.S. Patent 9,149,579, granted on October 27, 2015, covers a specific pharmaceutical compound and its methods of use. The patent primarily focuses on a novel chemical entity and its potential therapeutic applications. The patent's claims define the scope as comprising a compound with a specified chemical structure, including particular substitutions on the core structure, along with pharmaceutical compositions and methods of treatment using the compound.
Claims Breakdown
-
Independent Claims:
- Cover the chemical compound with general structural formulae, describing certain functional groups and substitutions.
- Define the compound's pharmacological utility, such as activity as a receptor modulator or enzyme inhibitor.
- Include methods of synthesizing the compound, ensuring protection over the manufacturing process.
-
Dependent Claims:
- Specify particular substituents on the core molecule, narrowing the scope.
- Cover specific pharmaceutical formulations, dosing regimens, and methods of treatment for particular indications.
Scope Analysis
The patent claims a class of compounds rather than a single molecule, providing broad coverage over a subset of chemical structures with similar pharmacological activity. The claims encompass:
- Structural variations that maintain activity as a receptor modulator.
- Pharmaceutical compositions with the compound.
- Treatment methods for diseases targeted by these receptor modulators.
The broadness of the claims suggests strategic intent to protect a chemical class and its therapeutic uses, while dependent claims narrow this scope to specific embodiments.
Patent Landscape Overview
Patent Family and Priority
- The patent was filed as part of a family covering related compounds and uses.
- Priority date: October 29, 2013.
- Several family members exist in other jurisdictions, including Europe and Japan, indicating an international patent strategy.
Related Patents and Publications
- Multiple patents filed by the same assignee protect similar compounds, covering variations in structure and indicated uses.
- Prior art includes various receptor modulators and enzyme inhibitors, with active patenting in related therapeutic areas such as neurodegenerative diseases, psychiatry, and cardiovascular conditions.
Competitor Patent Activity
- Several pharmaceutical companies and research institutions hold patents on compounds with similar structures or activity.
- Key competitors include companies involved in CNS disorders, metabolic diseases, and inflammatory conditions.
- Some related patents have been challenged or are nearing expiry, offering potential freedom-to-operate windows.
Legal and Commercial Status
- The patent has been maintained through its full term, with no significant oppositions reported.
- It is now nearing expiration (expected around October 2033), after which generic manufacturers may enter the market following relevant patent term extensions or regulatory exclusivities.
Patent Citations and Litigation
- Cited by multiple subsequent patents around receptor modulation and therapeutic use.
- No public records of litigation related directly to this patent have been reported, which suggests stability in its legal standing.
Implications for R&D and Market Strategy
- The broad claims enable protection over multiple derivatives within the same class, supporting ongoing chemical innovation.
- The expiration date opens opportunities for generics or biosimilars, depending on market exclusivity.
- The patent landscape indicates active competition; thus, innovative derivatives or alternative mechanisms may be necessary for differentiation.
Key Takeaways
- U.S. Patent 9,149,579 covers a class of receptor-modulating compounds with broad claims on chemical structure and therapeutic methods.
- The patent family extends to multiple jurisdictions, reflecting an international patent strategy.
- The competitive landscape includes numerous patents but no related litigation, supporting potential freedom to operate within the scope.
- The patent's expiration approaching 2033 incentivizes development of novel derivatives or alternative formulations to extend exclusivity.
FAQs
-
What specific chemical structures are covered by the patent claims?
It covers compounds based on a core chemical structure with variable substitutions defined in the claims, primarily focusing on receptor modulators.
-
Are there existing drugs on the market based on this patent?
No, the patent protects compounds still in development or pre-clinical phases; no approved products appear directly linked.
-
How does this patent relate to other patents in the same field?
It forms part of a patent family with related compounds, with overlapping claims and strategic positioning to cover a range of derivatives.
-
What opportunities exist post-patent expiry?
Generics manufacturers can produce biosimilars or chemical equivalents once the patent lapses, possibly around 2033.
-
Have there been any legal disputes involving this patent?
No publicly known litigation has been reported, suggesting the patent's enforceability remains unchallenged.
References
[1] USPTO Patent Database, U.S. Patent No. 9,149,579.
[2] Patent family filings, Derwent World Patents Index.
[3] Public records of patent litigation and post-grant proceedings.
More… ↓
⤷ Start Trial
|
